Titre (Assay): Standardisé à 40 % d'asiaticoside et 60 % de génines (acide madécassique et acide asiatique)
Particle Size: Fourni sous forme de poudre pour formulation orale et topique à des taux d'utilisation de 0,1 % à 1 %
Profil d'impuretés: Extrait de Centella asiatica sous contrôle qualité, avec plus de 50 ans d'utilisation documentée dans les produits médicamenteux de cicatrisation et d'insuffisance veineuse

Autres informations

Description supplémentaire:

TECA Pharma is the first Centella asiatica extract approved for medicinal use, backed by 50 years of application in wound-healing and venous-insufficiency drug products. Its INCI listing covers asiaticoside, madecassic acid, and asiatic acid, supplied as a powder containing 40% asiaticoside and 60% genins, used at 0.1-1% in oral and topical applications, with end-product status spanning marketing authorization, over-the-counter, and medical device categories. As a titrated Centella asiatica extract with demonstrated biological activity, it promotes collagen synthesis by stimulating dermal fibroblasts, modulates angiogenesis, and stimulates extracellular matrix remodeling. It is produced under Good Manufacturing Practice, with an Active Substance Master File (ASMF) and full toxicological/tolerance data available on request.